Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 655-659 , November 2004

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer: Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.

References 

  1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: The global picture. Eur J Cancer. 2001;37(Suppl 8):S4–S66
  2. Lopez PG, Stewart DJ, Newman TE, Evans WK Provincial Lung Disease Site Group. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Cancer Prevention and Control. 1997;1:18–27
  3. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced NSCLC: A Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–3218
  4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced NSCLC. N Engl J Med. 2002;346:92–93
  5. Wells A. The epidermal growth factor receptor (EGFR): A new target in cancer therapy. Signal. 2000;1:4–11
  6. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241–250
  7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with NSCLC: a randomized trial. JAMA. 2003;290:2149–2158
  8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced NSCLC. J Clin Oncol. 2003;21:2237–2246
  9. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor – selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053–2063
  10. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenograts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885–4892

☆ Sources of funding: This study was funded by Astra Zeneca, Wilmington, Delaware, USA.

☆ For Correspondence: Roy Herbst, Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Holcombe Blvd, Houston, TX, USA. E-mail: rherbst@mail.mdanderson.org

☆☆ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(04)00144-6

doi: 10.1016/j.ctrv.2004.08.002

Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 655-659 , November 2004

Article Tools